Skip to content

NPPV Added Inspiratory Muscle Training in Severe COPD

Noninvasive Positive Pressure Ventilation Added Inspiratory Muscle Training in Severe Chronic Obstructive Pulmonary Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01926275
Enrollment
80
Registered
2013-08-20
Start date
2013-07-31
Completion date
2013-12-31
Last updated
2013-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease, Hypercapnic Respiratory Failure

Keywords

COPD, Noninvasive Positive Pressure Ventilation, Respiratory Muscle Training

Brief summary

The aim of this study is to determine whether noninvasive positive pressure ventilation with inspiratory muscle training can improve quality of life and respiratory muscle strength than noninvasive positive pressure ventilation or inspiratory muscle training alone.

Interventions

DEVICENPPV+IMT

noninvasive positive pressure ventilation and inspiratory muscle training

DEVICENPPV

noninvasive positive pressure ventilation

DEVICEIMT

inspiratory muscle training

Sponsors

Guangzhou Institute of Respiratory Disease
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Aged 40-75 years, male or female. 2. Have spirometric evidence of COPD with an FEV1 of \< 50% predicted and FEV1/FVC \< 0.70, measured within the last 6 months (GOLD stage III and IV). Stable disease since 4 weeks or more prior to randomisation. 3. PCO2 of 7 kPa, combined with a pH of 7.35 or above. These gases must be measured after 30 minutes breathing room air in sitting position 4. No treatment with NPPV and respiratory muscle training in the last 8 weeks

Exclusion criteria

1. Smokers can be excluded; 2. Diseases of the lung or thorax besides COPD: OSA Advanced pulmonary fibrosis, advanced bronchiectases, active tuberculosis, post tuberculosis syndrome, pneumonia, severe kyphoscoliosis, tracheostoma, neuromuscular diseases, or any other disorder, which might result in elevated PCO2 3. Body mass index of 35 kg/m² or above. Severe cardiac disease, NYHA IV, instable angina, severe cardiac arrhythmia, especially of ventricular origin (atrial fibrillation is not an exclusion criterion). 4. Local derangement of the face, skin, tongue, upper airways, larynx and upper oesophagus. 5. Severe chronic diseases except COPD, hindering the patient to follow the schedule of this study

Design outcomes

Primary

MeasureTime frameDescription
Quality of lifeChange from Baseline in quality of life at 8 weeksSevere Respiratory Insufficiency (SRI) Questionnaire and chronic obstructive pulmonary disease assessment test(CAT)

Secondary

MeasureTime frameDescription
DyspneaChange from Baseline in dyspnea at 8 weeksbaseline dyspnea index (BDI)and transition dyspnea index(TDI)
Walked distance in 6MWTChange from Baseline in walked distance at 8 weeksChange from baseline in distance walked test 6-minute walk test at 8 week
Frequency of acute exacerbations of COPD8 week
Pulmonary function testsChange from Baseline in pulmonary function tests at 8 weeks
respiratory muscle strengthChange from Baseline in respiratory muscle strength at 8 weeks
Sleep qualityChange from Baseline in sleep qualityat 8 weeksEpworth´s Sleepiness Scale
Length of hospital admission8 week
frequency of of hospital admission8 week
Blood gases levelsChange from Baseline in blood gases levelsat 8 weeks

Countries

China

Contacts

Primary ContactLuQian Zhou, Doctor
zhlx09@163.com+86-15622236759

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026